CD56+ CD7+ Stem Cell Leukemia/Lymphoma with D2-J.DELTA.1 Rearrangement.

Yoshida, Takemi; Kimura, N.; Sawada, Hitoshi; Suematsu, Eiichi; Nagano, Mitsuyuki; Akiyoshi, T; Motomura, S; Kikuchi, Masahiro; Nishimura, Junji; Tamura, Kazuo

doi:10.2169/internalmedicine.38.547

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD56 positivity was in three patients (25%) with AML and in one patient (10%) with ALL. These results are higher than other studies in the literature (1,2,4,5,7,8). This may be due to minority of patient population or regional properties.…”

Section: Discussioncontrasting

confidence: 75%

“…CD56 antigen, a member of immunoglobulin supergene family, is expressed especially on human NK cells and a minor subset of T cells mediating major histocompatibility complex (MHC)‐non‐restricted cytotoxicity (4,6,7). The CD56 antigen has been found to correspond to a neural cell adhesion molecule with homophilic binding characteristics.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The importance of CD7 and CD56 antigens in acute leukaemias

Tiftik

Bolaman

Batun

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

The prognostic significance of immunophenotypical properties of leukaemic cells is well known. However, the biological and clinical significance of CD7 and CD56 antigen expression in acute leukaemias are not clearly established. In patients with acute leukaemias, we identified CD7 and CD56 expression and analysed their associations with markers expressed early in haemopoietic ontogeny and clinical parameters. Among 22 patients with acute leukaemia [12 acute myeloblastic leukaemia (AML), 10 acute lymphoblastic leukaemia (ALL)], we found CD7 positivity in 15 of 22 patients (68%) and CD56 positivity in four patients (18%). CD7 positivity was observed in seven patients (58%) with AML and in eight patients (80%) with ALL. CD56 positivity was observed in three patients (25%) with AML and one patient (10%) with ALL. Lymphadenopathy was present in five patients and associated with hepatosplenomegaly in three patients with ALL. Splenomegaly and hepatomegaly were present in three patients with AML. Central nervous system involvement was seen in one patient with ALL. Complete remission was achieved in nine patients (41%) (five ALL and four AML). Our data showed that CD7 and CD56 positivity at diagnosis associated with low remission rate and biological aggressiveness in a significant proportion of patients. We suggest the evaluation of CD7 and CD56 in all patients with acute leukaemias at the time of diagnosis in view of poor clinical outcome.

show abstract

Section: Discussioncontrasting

confidence: 75%

Section: Introductionmentioning

confidence: 99%

The importance of CD7 and CD56 antigens in acute leukaemias

Tiftik

Bolaman

Batun

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

Ocena ekspresji cząsteczki CD1d na limfocytach B u chorych na przewlekłą białaczkę limfocytową

Woś

Bojarska‐Junak

Hus

et al. 2013

Acta Haematologica Polonica

View full text Add to dashboard Cite

Non-B, Non-T Neoplasms With Lymphoblast Morphology

Karube

Ohshima

Tsuchiya

et al. 2003

The American Journal of Surgical Pathology

View full text Add to dashboard Cite

We studied the morphologic, immunohistochemical, and clinical characteristics of 158 cases of lymphoblastic lymphoma. Based on immunophenotyping and cell lineage, cases were classified into B-cell type (CD20,CD19 or CD79a+, n = 53), T-cell type (surface CD3+, n = 84), and non-B, non-T type (B cell marker- and surface CD3-, n = 21). The latter group was further divided based on immunohistochemistry into: 1) CD7+ stem cell lymphoma (CD7+SCL) [CD4-, CD7+, CD33+/-, CD56-], 2) blastic natural killer cell lymphoma (B-NKL) [CD4-, CD7+/-, CD33-, CD56+, CD123-], 3) myeloid/NK precursor cell leukemia (M/NKL) [CD4-, CD7+, CD33+, CD56+], and 4) CD4+CD56+ hematodermic malignancy (CD4+CD56+) type [CD4+, CD7+/-, CD33-, CD56+, CD123+]. The CD7+SCL and M/NKL types frequently exhibited bone marrow invasion and mediastinal masses. All CD4+CD56+ types were associated with skin lesions. B-NKL type is included into Blastic NK lymphoma in new World Health Organization classification with CD4+CD56+ type. But the cases of B-NKL were more reminiscent of CD7+SCL or M/NKL type than the CD4+CD56+ type, both clinically and histologically. We propose that blastic NK lymphoma, a disease entity in the new WHO classification, should be divided into two types based on phenotypes and clinical features. The non-B, non-T lymphomas exhibited poorer prognoses, similar to that of B-cell lymphomas, than T-cell type tumors (P = 0.009). Among the 21 tumors, the prognosis of the four subtypes did not differ significantly; however, cases receiving aggressive chemotherapy and stem cell transplantation had a more favorable prognosis than those receiving only traditional chemotherapy and radiation therapy (P = 0.0089).

show abstract

CD56+ CD7+ Stem Cell Leukemia/Lymphoma with D2-J.DELTA.1 Rearrangement.

Cited by 4 publications

References 41 publications

The importance of CD7 and CD56 antigens in acute leukaemias

The importance of CD7 and CD56 antigens in acute leukaemias

Ocena ekspresji cząsteczki CD1d na limfocytach B u chorych na przewlekłą białaczkę limfocytową

Non-B, Non-T Neoplasms With Lymphoblast Morphology

Contact Info

Product

Resources

About